title: Author reply: To PMID 25442759.
authors.affiliation: Departments of, Infectious Diseases and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
authors.forename: R J
authors.initials: RJ
authors.lastname: Commons
authors.affiliation: Departments of, Infectious Diseases and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, Northern Territory, Australia.|Immunology, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Hannah
authors.affiliation: Departments of, Infectious Diseases and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, Northern Territory, Australia.|Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia.
authors.forename: B J
authors.initials: BJ
authors.lastname: Currie
mesh_terms: D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage*; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008554:Melioidosis / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D019980:Amoxicillin-Potassium Clavulanate Combination